Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer

被引：3

作者：

Mizuno, Nobumasa

Yamao, Kenji

Komatsu, Yoshito

Munakata, Masaki

Ishiguro, Atsushi

Yamaguchi, Taketo

Ohkawa, Shinichi

Kida, Mitsuhiro

Ioka, Tatsuya

Takeda, Koji

Kudo, Toshihiro

Kitano, Masayuki

Iguchi, Haruo

Tsuji, Akihito

Ito, Tetsuhide

Tanaka, Masao

Furuse, Junji

Hamada, Chikuma

Sakata, Yuh

机构：

[1] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 464, Japan

[2] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido, Japan

[3] Misawa City Hosp, Dept Med Oncol, Misawa, Japan

[4] Hirosaki Univ, Dept Med Oncol, Hirosaki, Aomori, Japan

[5] Chiba Canc Ctr, Div Gastroenterol, Chiba 2608717, Japan

[6] Kanagawa Canc Ctr Hosp, Hepatobiliary & Pancreat Oncol Div, Yokohama, Kanagawa, Japan

[7] Kitasato Univ, Sch Med, Dept Med, Sagamihara, Kanagawa 228, Japan

[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Hepatobiliary & Pancreat Oncol, Osaka, Japan

[9] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

[10] Kinki Univ, Dept Med Oncol, Osaka, Japan

[11] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan

[12] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan

[13] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan

[14] Kyushu Univ, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan

[15] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan

[16] Kyorin Univ, Sch Med, Dept Internal Med, Mitaka, Tokyo 181, Japan

[17] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

263

引用

页数：1

共 50 条

[31] RANDOMIZED PHASE II TRIAL OF S-1 PLUS IRINOTECAN VERSUS S-1 PLUS PACLITAXEL AS FIRST-LINE TREATMENT FOR ADVANCED GASTRIC CANCER (OGSG0402)
Fujitani, K.
Takiuchi, H.
Sugimoto, N.
Imamura, H.
Iijima, S.
Imano, M.
Kimura, Y.
Kurokawa, Y.
Tsujinaka, T.
Furukawa, H.
ANNALS OF ONCOLOGY, 2010, 21 : 256 - 256
[32] Gemcitabine plus S-1 for metastatic pancreatic cancer
Zhu, Hong
Yi, Cheng
Zhao, Yaqin
Gou, Hongfeng
MEDICINE, 2018, 97 (41)
[33] Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients
Kim, Hyun Jung
Yun, Jina
Kim, Han Jo
Kim, Kyoung Ha
Kim, Se Hyung
Lee, Tae Hoon
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Lee, Nam Su
Moon, Jong Ho
Park, Sang Heum
Lee, Kyu Taek
Park, Seong Kyu
Won, Jong-Ho
Park, Hee Sook
Hong, Dae Sik
ONCOLOGY LETTERS, 2012, 3 (06) : 1314 - 1318
[34] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
Morizane, Chigusa
Okusaka, Takuji
Ueno, Hideki
Kondo, Shunsuke
Ikeda, Masafumi
Furuse, Junji
Shinichi, Ohkawa
Nakachi, Kohei
Mitsunaga, Shuichi
Kojima, Yasushi
Suzuki, Eiichiro
Ueno, Makoto
Yamaguchi, Tomohiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 957 - 964
[35] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
Chigusa Morizane
Takuji Okusaka
Hideki Ueno
Shunsuke Kondo
Masafumi Ikeda
Junji Furuse
Ohkawa Shinichi
Kohei Nakachi
Shuichi Mitsunaga
Yasushi Kojima
Eiichiro Suzuki
Makoto Ueno
Tomohiro Yamaguchi
Cancer Chemotherapy and Pharmacology, 2012, 69 : 957 - 964
[36] The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study
Nakai, Y.
Isayama, H.
Sasaki, T.
Sasahira, N.
Hirano, K.
Tsujino, T.
Tada, M.
Kawabe, T.
Omata, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[37] Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
K Nakamura
T Yamaguchi
T Ishihara
K Sudo
H Kato
H Saisho
British Journal of Cancer, 2006, 94 : 1575 - 1579
[38] Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
Nakamura, K.
Yamaguchi, T.
Ishihara, T.
Sudo, K.
Kato, H.
Saisho, H.
BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1575 - 1579
[39] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP.
Kawase, Tomono
Imamura, Hiroshi
Gotoh, Masahiro
Kimura, Yutaka
Ueda, Shugo
Matsuyama, Jin
Nishikawa, Kazuhiro
Sugimoto, Naotoshi
Fujita, Junya
Tamura, Takao
Fukushima, Norimasa
Kawabata, Ryohei
Kurokawa, Yukinori
Shimokawa, Toshio
Sakai, Daisuke
Tsujinaka, Toshimasa
Furukawa, Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)
Morizane, Chigusa
Okusaka, Takuji
Mizusawa, Junki
Takashima, Atsuo
Ueno, Makoto
Ikeda, Masafumi
Hamamoto, Yasuo
Ishii, Hiroshi
Boku, Narikazu
Furuse, Junji
CANCER SCIENCE, 2013, 104 (09): : 1211 - 1216

← 1 2 3 4 5 →